Related Experiment Video
Updated: May 17, 2026
06:04
Ex Vivo Intestinal Sacs to Assess Mucosal Permeability in Models of Gastrointestinal Disease
Published on: February 9, 2016
Lubiprostone stimulates small intestinal mucin release
1Anatomy and Cell Biology, University of Kansas School of Medicine, Kansas City, KS 66160, USA. rdelisle@kumc.edu
BMC Gastroenterology
|November 8, 2012
Summary
Lubiprostone, a drug for chronic constipation, stimulates intestinal mucin release when applied to the serosal side, similar to prostaglandin actions. This suggests potential therapeutic uses beyond constipation by promoting protective mucus secretion.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Lubiprostone is a prostaglandin E1 derivative used for chronic constipation.
- Its known action involves stimulating chloride-dependent fluid secretion.
- Previous studies indicated increased mucus in cystic fibrosis mouse models treated with lubiprostone.
Purpose of the Study:
- To investigate whether lubiprostone directly stimulates intestinal mucin release.
- To explore the mechanism of lubiprostone's effect on intestinal mucus production.
Main Methods:
- Mouse small intestine segments were mounted in an organ bath.
- Mucin release was measured in perfusate and bath solutions.
- Lubiprostone was applied luminally or serosally, with smooth muscle and prostaglandin synthesis inhibitors present.
Main Results:
- Luminal application of 1 μM lubiprostone did not stimulate mucin release.
- Serosal application of 1 μM lubiprostone increased mucin release by approximately 300%.
- Prostaglandin E2 (1 μM, serosal) increased mucin release by approximately 400%.
Conclusions:
- Lubiprostone exhibits prostaglandin-like effects on the intestine, including mucin release stimulation.
- Stimulation of mucin release may offer protection in gastrointestinal conditions involving mucus loss.
- Lubiprostone has potential therapeutic applications beyond chronic constipation.
Related Concept Videos
01:21Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
01:22Drugs Affecting GI Tract Motility: Bulk-Forming and Stimulant Laxatives
Laxatives enhance bowel movements and alleviate constipation. They augment the stool's bulk, stimulate intestinal muscle contractions, draw water into the intestines, or soften the stool. There are five key types of laxatives: bulk laxatives, stimulant laxatives, osmotic laxatives, stool softeners, and lubricant laxatives.
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
Bulk-forming laxatives, such as psyllium, methylcellulose, and polycarbophil, absorb water in the intestine, increasing stool bulk and promoting bowel movement. This makes...
01:20Drugs Affecting GI Tract Motility: Other Laxatives
Laxatives are primarily used to alleviate constipation, a common gastrointestinal disorder characterized by infrequent bowel movements and difficulty passing stools. They work by various mechanisms to increase the volume or frequency of bowel movements. The primary modes of action of laxatives include increasing stool bulk, softening the stool, stimulating intestinal motility, and osmotically drawing water into the intestines.
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
Osmotic or saline laxatives, like magnesium hydroxide or milk of...
01:29Intestinal Phase of Digestion
The intestinal phase of digestion is the third and final stage of the digestive process, occurring after the cephalic and gastric phases. It begins when chyme, a partially digested mixture of food and digestive enzymes, enters the small intestine from the stomach. This phase is crucial for nutrient absorption and involves complex hormonal and enzymatic interactions.
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
The arrival of the chyme in the small intestine distends the duodenum, which triggers the enterogastric reflex. This distension...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...